Drug Approval | June 06, 2022
FDA publishes ANP’s polymeric drug excipient DMF
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
The companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage.
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
Susanne Kaestner joins the company as Senior Vice President, Quality and member of the Executive Team, and Dr. Thea Boehm as Vice President, Business Development.
A research group led by Ben-Gurion University of the Negev managed to produce an innovative microchip for creating sperm in a culture by using a microfluidic system.
PharmaLytica Expo to aid in chalking out pharma industry’s $130 Billion growth story by 2030
Innate to receive $5M milestone payment from AstraZeneca
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
Follows Zealand Pharma’s appointment of Adam Steensberg as CEO and decision to refocus strategy
The proposed demerger is the most significant corporate change for GSK in the last 20 years
Subscribe To Our Newsletter & Stay Updated
